Celltrion FY 2025 Annual ReportBeta
Celltrion annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 16, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
Celltrion FY 2025 Annual Report Analysis
Business Overview
- • Celltrion: global biosimilar leader; 11 approved biosimilar products + Zymfentra (CT-P13 SC) FDA novel drug approval; direct-sales model across EU, US, key markets
- • FY2025 revenue KRW 4,163B (+17% YoY), operating profit KRW 1,169B; biosimilars 93% of sales
Management Discussion & Analysis
- • Consolidated revenue KRW 4.16T (+17% YoY), operating profit KRW 1.17T (+137% YoY), net income KRW 1.03T (+146% YoY)
- • OP margin expanded to 28.1% (+14.2%p YoY); driven by full normalization of post-merger cost spike, improved product mix toward higher-margin new products, and SG&A leverage
Risk Factors
- • FX sensitivity: 8% move in USD/EUR/GBP/JPY/CHF impacts pre-tax profit by ±KRW 312.3B (2025) vs ±KRW 39.3B (2024) — EUR alone ±KRW 220.0B
- • Total borrowings surged to KRW 3,690B (2025) from KRW 2,162B (2024); net debt ratio doubled to 12.90% from 6.22%; debt ratio rose to 28.71% from 19.77%
Celltrion FY 2025 Key Financial MetricsDART
Revenue
KRW 4.16T
Net Income
KRW 1.03T
Gross Margin
59.3%
Operating Margin
28.1%
Net Margin
24.8%
ROE
6.0%
Total Assets
KRW 22.33T
EPS (Diluted)
KRW 4,660
Operating Cash Flow
KRW 646.1B
CapEx
KRW 108.2B
Source: KIFRS consolidated financial data from Celltrion annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding